276 related articles for article (PubMed ID: 23458935)
1. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
[TBL] [Abstract][Full Text] [Related]
2. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
[TBL] [Abstract][Full Text] [Related]
3. The impact of genotype on endocrine complications in thalassaemia major.
Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
[TBL] [Abstract][Full Text] [Related]
4. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
Gamberini MR; De Sanctis V; Gilli G
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
6. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
7. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
8. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.
Telfer PT; Prestcott E; Holden S; Walker M; Hoffbrand AV; Wonke B
Br J Haematol; 2000 Sep; 110(4):971-7. PubMed ID: 11054091
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
10. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia.
Kurtoglu AU; Kurtoglu E; Temizkan AK
Endokrynol Pol; 2012; 63(4):260-3. PubMed ID: 22933160
[TBL] [Abstract][Full Text] [Related]
11. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
[TBL] [Abstract][Full Text] [Related]
12. Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre.
Almahmoud R; Hussein A; Khaja FA; Soliman AF; Dewedar H; Shareef ZA; Mathai S
BMC Pediatr; 2024 Apr; 24(1):244. PubMed ID: 38580952
[TBL] [Abstract][Full Text] [Related]
13. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
Ang AL; Tzoulis P; Prescott E; Davis BA; Barnard M; Shah FT
Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
[TBL] [Abstract][Full Text] [Related]
14. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
Liang Y; Bajoria R; Jiang Y; Su H; Pan H; Xia N; Chatterjee R; Lai Y
Trop Med Int Health; 2017 Jun; 22(6):716-724. PubMed ID: 28544032
[TBL] [Abstract][Full Text] [Related]
17. Treatment and complications of thalassemia major in Guangxi, Southern China.
Yin XL; Wu ZK; He YY; Zhou TH; Zhou YL; Zhang XH
Pediatr Blood Cancer; 2011 Dec; 57(7):1174-8. PubMed ID: 21394896
[TBL] [Abstract][Full Text] [Related]
18. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.
Chern JP; Lin KH
J Pediatr Hematol Oncol; 2002 May; 24(4):291-3. PubMed ID: 11972098
[TBL] [Abstract][Full Text] [Related]
19. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
[TBL] [Abstract][Full Text] [Related]
20. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
